FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1748441280> ?p ?o ?g. }

• W1748441280 endingPage "3194" @default.
• W1748441280 startingPage "3188" @default.
• W1748441280 abstract "Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.Ambulatory patients with NSCLC, aged 75 years or younger, with localized disease, were randomized in MIC1 to receive up to four cycles of chemotherapy (CT: mitomycin 6 mg/m(2), ifosfamide 3 g/m(2), and cisplatin 50 mg/m(2)) every 21 days, followed by radical radiotherapy (CT + RT) or radiotherapy (RT) alone. Extensive-stage patients were randomized in MIC2 to identical chemotherapy plus palliative care (CT + PC) or palliative care (PC) alone. Short-term change in quality of life (QOL) was assessed in a subgroup of patients. Data from the two trials were combined to allow multivariate and stratified survival analyses.Seven hundred ninety-seven eligible patients were randomized, 446 in MIC1 and 351 in MIC2. MIC CT improved survival in both trials (significantly in MIC2). The median survival time in MIC1 was 11.7 months (CT + RT) versus 9.7 months (RT alone) (P =.14); whereas in MIC2, median survival time was 6.7 months (CT + PC) compared with 4. 8 months (PC alone) (P =.03). QOL, assessed in 134 patients from start of trial to week 6, showed improvement with chemotherapy and deterioration with standard treatment. In the combined analysis of 797 randomized patients, the positive effect of MIC on survival was significant overall (P =.01) and after adjusting for prognostic factors (P =.01).MIC chemotherapy prolongs survival in unresectable NSCLC without compromising QOL." @default.
• W1748441280 created "2016-06-24" @default.
• W1748441280 creator A5001518016 @default.
• W1748441280 creator A5011734499 @default.
• W1748441280 creator A5035278067 @default.
• W1748441280 creator A5036848123 @default.
• W1748441280 creator A5039491597 @default.
• W1748441280 creator A5047032886 @default.
• W1748441280 creator A5050771632 @default.
• W1748441280 creator A5062675479 @default.
• W1748441280 creator A5069406714 @default.
• W1748441280 creator A5072059432 @default.
• W1748441280 creator A5072152561 @default.
• W1748441280 creator A5073547589 @default.
• W1748441280 creator A5082102746 @default.
• W1748441280 creator A5082320956 @default.
• W1748441280 creator A5085688805 @default.
• W1748441280 date "1999-10-01" @default.
• W1748441280 modified "2023-10-16" @default.
• W1748441280 title "Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life" @default.
• W1748441280 cites W1922104747 @default.
• W1748441280 cites W1942454844 @default.
• W1748441280 cites W1968765750 @default.
• W1748441280 cites W1978156658 @default.
• W1748441280 cites W1986335982 @default.
• W1748441280 cites W2014145691 @default.
• W1748441280 cites W2016691736 @default.
• W1748441280 cites W2049190121 @default.
• W1748441280 cites W2061961646 @default.
• W1748441280 cites W2084803292 @default.
• W1748441280 cites W2100745882 @default.
• W1748441280 cites W2104325484 @default.
• W1748441280 cites W2129793485 @default.
• W1748441280 cites W2133514662 @default.
• W1748441280 cites W2138310931 @default.
• W1748441280 cites W2138945505 @default.
• W1748441280 cites W2140045873 @default.
• W1748441280 cites W2155053061 @default.
• W1748441280 cites W2167571044 @default.
• W1748441280 cites W2179191690 @default.
• W1748441280 cites W2229315518 @default.
• W1748441280 cites W2262092684 @default.
• W1748441280 cites W2328451703 @default.
• W1748441280 cites W3147894994 @default.
• W1748441280 cites W4239714259 @default.
• W1748441280 cites W4293241248 @default.
• W1748441280 doi "https://doi.org/10.1200/jco.1999.17.10.3188" @default.
• W1748441280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10506617" @default.
• W1748441280 hasPublicationYear "1999" @default.
• W1748441280 type Work @default.
• W1748441280 sameAs 1748441280 @default.
• W1748441280 citedByCount "435" @default.
• W1748441280 countsByYear W17484412802012 @default.
• W1748441280 countsByYear W17484412802013 @default.
• W1748441280 countsByYear W17484412802014 @default.
• W1748441280 countsByYear W17484412802015 @default.
• W1748441280 countsByYear W17484412802016 @default.
• W1748441280 countsByYear W17484412802017 @default.
• W1748441280 countsByYear W17484412802018 @default.
• W1748441280 countsByYear W17484412802019 @default.
• W1748441280 countsByYear W17484412802020 @default.
• W1748441280 countsByYear W17484412802021 @default.
• W1748441280 countsByYear W17484412802022 @default.
• W1748441280 countsByYear W17484412802023 @default.
• W1748441280 crossrefType "journal-article" @default.
• W1748441280 hasAuthorship W1748441280A5001518016 @default.
• W1748441280 hasAuthorship W1748441280A5011734499 @default.
• W1748441280 hasAuthorship W1748441280A5035278067 @default.
• W1748441280 hasAuthorship W1748441280A5036848123 @default.
• W1748441280 hasAuthorship W1748441280A5039491597 @default.
• W1748441280 hasAuthorship W1748441280A5047032886 @default.
• W1748441280 hasAuthorship W1748441280A5050771632 @default.
• W1748441280 hasAuthorship W1748441280A5062675479 @default.
• W1748441280 hasAuthorship W1748441280A5069406714 @default.
• W1748441280 hasAuthorship W1748441280A5072059432 @default.
• W1748441280 hasAuthorship W1748441280A5072152561 @default.
• W1748441280 hasAuthorship W1748441280A5073547589 @default.
• W1748441280 hasAuthorship W1748441280A5082102746 @default.
• W1748441280 hasAuthorship W1748441280A5082320956 @default.
• W1748441280 hasAuthorship W1748441280A5085688805 @default.
• W1748441280 hasConcept C126322002 @default.
• W1748441280 hasConcept C141071460 @default.
• W1748441280 hasConcept C143998085 @default.
• W1748441280 hasConcept C159110408 @default.
• W1748441280 hasConcept C168563851 @default.
• W1748441280 hasConcept C2776256026 @default.
• W1748441280 hasConcept C2776694085 @default.
• W1748441280 hasConcept C2777506904 @default.
• W1748441280 hasConcept C2778239845 @default.
• W1748441280 hasConcept C2779338040 @default.
• W1748441280 hasConcept C2781190966 @default.
• W1748441280 hasConcept C2994186709 @default.
• W1748441280 hasConcept C509974204 @default.
• W1748441280 hasConcept C71924100 @default.
• W1748441280 hasConceptScore W1748441280C126322002 @default.
• W1748441280 hasConceptScore W1748441280C141071460 @default.
• W1748441280 hasConceptScore W1748441280C143998085 @default.
• W1748441280 hasConceptScore W1748441280C159110408 @default.

• next